Voriconazole
Voriconazole hameln Contains the Active Substance Voriconazole. Voriconazole is an Antifungal Medication. It Works by Killing Fungi that Cause Infections or by Inhibiting their Growth.
The Medication is Used to Treat Patients (Adults and Children Over 2 Years Old) with:
Invasive Aspergillosis (a Type of Fungal Infection Caused by Fungi of the Genus Aspergillus spp.),
Candidemia (Another Type of Fungal Infection Caused by Fungi of the Genus Candidaspp.) in Patients Without Accompanying Neutropenia (Patients Without a Decreased Number of White Blood Cells),
Severe, Invasive Fungal Infections Caused by Fungi of the Genus Candidaspp.Resistant to Fluconazole (Another Antifungal Medication),
Severe Fungal Infections Caused by Fungi of the Genus Scedosporium spp.and Fusarium spp.(Two Different Species of Fungi).
Voriconazole is Intended for Patients with Progressive, Life-Threatening Fungal Infections.
The Medication is Also Intended to Prevent Fungal Infections in High-Risk Patients After Bone Marrow Transplantation.
This Medication Should Only be Used Under the Supervision of a Doctor.
It is Very Important to Inform the Doctor or Pharmacist About all Medications the Patient is Currently Taking or has Recently Taken, Including those Available Without a Prescription or Herbal Medications.
During Treatment with Voriconazole hameln, the Following Medications Should Not be Taken:
Before Starting Voriconazole, Discuss the Following with a Doctor, Pharmacist, or Nurse:
If the Patient has Experienced an Allergic Reaction to Other Azoles in the Past.
If the Patient has or has had Liver Disease. In the Case of Liver Disease, the Doctor may Prescribe a Lower Dose of Voriconazole. The Doctor should also Monitor the Patient's Liver Function During Voriconazole Treatment by Ordering Blood Tests.
If the Patient has been Diagnosed with Cardiomyopathy, Heart Rhythm Disorders, Slow Heart Rate, or Changes in the Electrocardiogram (ECG) Known as "Prolonged QTc Interval".
Avoid Exposure to Sunlight During Treatment. It is Important to Wear Protective Clothing and Use Sunscreen with a High Sun Protection Factor (SPF) when Exposed to Sunlight, as Sensitivity to Sunlight may Occur. This Sensitivity may be Increased by Other Medications that Make the Skin More Sensitive to Sunlight, such as Methotrexate. These Precautions Apply to Children as Well.
During Voriconazole Treatment, Inform the Doctor Immediately if the Following Occur:
Sunburn
Severe Skin Rash or Blisters
Bone Pain
If the Patient Experiences any of the Above Skin Disorders, the Doctor may Refer the Patient to a Dermatologist, who may Decide on the Need for Regular Follow-Up Visits. There is a Small Risk that Long-Term Use of Voriconazole may Cause Skin Cancer.
If the Patient Experiences Symptoms of "Adrenal Insufficiency"; a Condition in which the Adrenal Glands do not Produce Enough of Certain Steroid Hormones, such as Cortisol; which may Lead to Symptoms such as: Chronic or Prolonged Fatigue, Muscle Weakness, Loss of Appetite, Weight Loss, Abdominal Pain, Inform the Doctor.
If the Patient Experiences Symptoms of "Cushing's Syndrome", a Condition in which the Body Produces too Much of the Hormone Cortisol, which may Lead to Symptoms such as: Weight Gain, Appearance of a Hump of Fat Between the Shoulder Blades, Rounded Face, Darkening of the Skin on the Abdomen, Thighs, Chest, and Arms, Thinning of the Skin, Increased Susceptibility to Bruising, Increased Blood Sugar Levels, Excessive Hair Growth, Excessive Sweating, Inform the Doctor.
The Doctor should Regularly Monitor the Patient's Liver and Kidney Function by Ordering Blood Tests.
Voriconazole hameln Should Not be Used in Children Under 2 Years Old.
Inform the Doctor or Pharmacist About all Medications the Patient is Currently Taking or Plans to Take, Including those Available Without a Prescription.
Certain Medications Taken at the Same Time as Voriconazole may Change its Effect, and Voriconazole may Affect the Action of Other Medications.
Inform the Doctor About the Use of the Following Medication, as it Should be Avoided if Possible:
Inform the Doctor About the Use of any of the Following Medications, as it may be Necessary to Avoid their Concurrent Use with Voriconazole (if this is not Possible, the Dose of Voriconazole may Need to be Adjusted):
Inform the Doctor About the Use of any of the Following Medications, as it may be Necessary to Adjust or Monitor the Dosing of these Medications and/or Voriconazole to Ensure they Continue to have the Desired Effect:
If the Patient is Pregnant or Breastfeeding, Thinks they may be Pregnant, or Plans to Become Pregnant, they Should Consult a Doctor or Pharmacist Before Using this Medication.
Voriconazole hameln Should Not be Used During Pregnancy, Unless the Doctor Decides Otherwise.
During Treatment with Voriconazole hameln, Women of Childbearing Age Must Use Effective Contraception. If Pregnancy Occurs During Treatment with Voriconazole hameln, the Patient Should Immediately Consult a Doctor.
Voriconazole hameln may Cause Vision Disturbances or Abnormal Reactions to Light.
In Such Cases, the Patient Should Not Drive or Operate Machinery. The Patient Should Consult a Doctor if Such Disturbances Occur.
This Medication Contains 88.74 mg of Sodium (a Major Component of Table Salt) per Vial. This is Equivalent to 4.44% of the Maximum Recommended Daily Intake of Sodium in the Diet for Adults.
Inform the Doctor or Pharmacist if the Patient Needs 5 or More Vials per Day for an Extended Period, Especially if they have been Advised to Follow a Low-Sodium Diet.
This Medication Contains 2,400 mg of Hydroxypropylbetadex per Vial, which is Equivalent to 120 mg/mL if Reconstituted in 20 mL of Clear Concentrate.
If the Patient has Kidney Disease, they Should Consult a Doctor Before Using this Medication.
This Medication Should Always be Used as Directed by the Doctor. In Case of Doubts, Consult a Doctor.
The Doctor will Decide on the Dose of the Medication Based on the Patient's Body Weight and the Type of Infection.
The Doctor may Change the Recommended Dose Depending on the Patient's Clinical Condition.
The Usual Recommended Dosage for Adults (Including Elderly Patients) is Presented in the Following Table:
Intravenous | |
Loading Dose (First 24 Hours) | 6 mg/kg Body Weight Every 12 Hours for the First 24 Hours |
Maintenance Dose (After the First 24 Hours) | 4 mg/kg Body Weight Twice Daily |
Depending on the Response to Treatment, the Doctor may Reduce the Daily Dose to 3 mg/kg Body Weight Twice Daily.
In Case of Mild to Moderate Liver Cirrhosis, the Doctor may Decide to Reduce the Dose of the Medication.
The Usual Recommended Dosage for Children and Adolescents is Presented in the Following Table:
Intravenous | ||
Children Aged 2 to 12 Years and Adolescents Aged 12 to 14 Years with a Body Weight Below 50 kg | Adolescents Aged 12 to 14 Years with a Body Weight of 50 kg or More and Adolescents Over 14 Years Old | |
Loading Dose (First 24 Hours) | 9 mg/kg Body Weight Every 12 Hours for the First 24 Hours | 6 mg/kg Body Weight Every 12 Hours for the First 24 Hours |
Maintenance Dose (After the First 24 Hours) | 8 mg/kg Body Weight Twice Daily | 4 mg/kg Body Weight Twice Daily |
Depending on the Response to Treatment, the Doctor may Increase or Decrease the Daily Dose.
Voriconazole hameln, Powder for Solution for Infusion, will be Prepared by a Nurse or Pharmacist (See Information at the End of the Package Leaflet).
The Medication will be Administered by Intravenous Infusion at a Maximum Rate of 3 mg/kg Body Weight per Hour for 1 to 3 Hours.
If the Patient is Taking Voriconazole hameln to Prevent Fungal Infections and Experiences Adverse Reactions Related to Treatment, the Treating Doctor may Discontinue Voriconazole hameln Administration.
Since the Medication will be Administered Under the Close Supervision of Medical Personnel, Missing a Dose is Unlikely. However, if a Dose is Missed, Inform the Doctor or Pharmacist.
The Doctor will Decide How Long the Patient will Receive Voriconazole hameln; However, Treatment with Voriconazole hameln, Powder for Solution for Infusion, Should Not Exceed 6 Months.
Patients with Impaired Immune Systems or Severe Infections may Require Long-Term Treatment to Prevent Relapse of the Disease. If Clinical Improvement Occurs, the Route of Administration of Voriconazole hameln may be Changed from Intravenous to Oral.
If the Doctor Decides to Discontinue Treatment, there is No Need to Worry About the Consequences of Stopping the Medication.
In Case of Any Further Doubts About the Use of this Medication, Consult a Doctor, Pharmacist, or Nurse.
Like all Medications, Voriconazole hameln can Cause Side Effects, although not Everybody Gets them.
If Side Effects Occur, they are Usually Mild and Transient. However, some of them can be Serious and may Require Medical Intervention.
Rash
Jaundice; Changes in Liver Function Test Results
Pancreatitis
Very Common: (May Occur in More than 1 in 10 People):
Common: (May Occur in Up to 1 in 10 People):
Uncommon: (May Occur in Up to 1 in 100 People):
Rare: (May Occur in Up to 1 in 1,000 People):
Frequency Not Known: (Cannot be Estimated from Available Data):
Other Important Side Effects, the Frequency of which is Not Known, but which Should be Reported to a Doctor Immediately:
During Infusion of Voriconazole hameln, the Following Adverse Reactions have been Reported: (Flushes, Fever, Sweating, Increased Heart Rate, and Shortness of Breath). If these Symptoms Occur, the Doctor may Decide to Discontinue the Infusion.
Due to the Known Effect of Voriconazole hameln on the Liver and Kidneys, the Doctor will Order Monitoring of these Organs' Function through Blood Tests. The Patient Should also Inform the Doctor if they Experience Abdominal Pain or Changes in Stool Consistency.
There have been Reports of Skin Cancer in Patients Treated with Voriconazole hameln for a Long Time.
Sunburn or Severe Skin Reactions to Light or Sun Exposure have been Reported More Frequently in Children. If the Patient Experiences Skin Disorders, the Doctor may Refer them to a Dermatologist, who may Decide on the Need for Regular Follow-Up Visits. Increased Liver Enzyme Activity has also been Observed More Frequently in Children.
If any of these Side Effects Persist or are Troublesome, Inform a Doctor.
If any Side Effects Occur, Including those not Mentioned in this Package Leaflet, Inform a Doctor, Pharmacist, or Nurse.
Side Effects can be Reported Directly to the Department of Medicinal Product Monitoring
Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products
Jerozolimskie Avenue 181C, 02-222 Warsaw
Phone: +48 22 49 21 301
Fax: +48 22 49 21 309
Website: https://smz.ezdrowie.gov.pl
Side Effects can also be Reported to the Marketing Authorization Holder.
Reporting Side Effects will Help to Gather More Information on the Safety of this Medication.
Keep the Medication out of Sight and Reach of Children.
Do not Use this Medication After the Expiration Date Stated on the Packaging and Vial Label After: EXP. The Expiration Date Refers to the Last Day of the Specified Month.
Unopened Vial
There are no Special Storage Instructions for the Medication Before Opening.
Reconstituted and Diluted Product:
Chemical and Physical Stability has been Demonstrated for 72 Hours at 25°C and at 2-8°C. From a Microbiological Point of View, the Product Should be Used Immediately. If the Concentrate is not Used Immediately, the User is Responsible for the Storage Conditions and the Storage Time should not Exceed 24 Hours at 2-8°C (Refrigerator), Provided that Reconstitution/Dilution was Carried out Under Controlled and Validated Aseptic Conditions.
The Medication Should not be Disposed of via Wastewater or Household Waste. Ask a Pharmacist how to Dispose of Medications that are no Longer Needed. This will Help Protect the Environment.
The Active Substance of the Medication is Voriconazole.
Each Vial Contains 200 mg of Voriconazole. After Reconstitution, each mL of Solution Contains 10 mg of Voriconazole.
Other Ingredients of the Medication are Hydroxypropylbetadex, Sodium Chloride, Hydrochloric Acid (to Adjust pH)
Each Package Contains 1 Vial. Voriconazole hameln is a White or Off-White Freeze-Dried Powder for Solution for Infusion in a 25 mL Type I Glass Vial with a Grey Rubber Stopper Type I, an Aluminium Seal, and a Red Plastic Flip-Off Cap.
hameln pharma gmbh
Inselstrasse 1
31787 Hameln
Germany
Phone: +49 171 766 2789
Anfarm Hellas S.A.
61 Km National Road Athens Lamia
32009 Schimatari Viotias
Greece
Pharmathen S.A.
6, Dervenakion street
Pallini 15351 Attiki
Greece
Austria
Voriconazol hameln 200 mg Powder for Solution for Infusion
Belgium
Voriconazol hameln 200 mg Powder for Solution for Infusion/Pulver zur Herstellung einer Infusionslösung/Powder for Solution for Infusion
Bulgaria
Вориконазол hameln 200mg Прах за инфузионен разтвор
Czech Republic
Voriconazole hameln
Denmark
Voriconazole "hameln"
Finland
Voriconazole hameln 200 mg Powder for Solution for Infusion
Ireland
Voriconazole 200mg Powder for Solution for Infusion
Netherlands
Voriconazol hameln 200 mg Powder for Solution for Infusion
Germany
Voriconazol hameln 200 mg Pulver zur Herstellung einer Infusionslösung
Norway
Voriconazole hameln
Poland
Voriconazole hameln
Portugal
Voriconazol hameln 200 mg Powder for Solution for Infusion
Romania
Voriconazol hameln 200 mg Pulbere pentru soluţie perfuzabilă
Slovakia
Voriconazole hameln 200 mg Powder for Solution for Infusion
Slovenia
Vorikonazol hameln 200 mg Prašek za raztopino za infundiranje
Sweden
Voriconazole hameln 200 mg Powder for Solution for Infusion
Italy
Voriconazolo hameln
---------------------------------------------------------------------------------------------------------------------------
Information Intended for Healthcare Professionals Only:
Required Volumes of Voriconazole hameln Concentrate 10 mg/mL
Voriconazole hameln is a Non-Preserved, Sterile Lyophilisate Intended for Single Use. From a Microbiological Point of View, the Solution for Infusion Should be Used Immediately After Reconstitution and Dilution. If the Concentrate is not Used Immediately, the User is Responsible for the Storage Conditions and the Storage Time should not Exceed 24 Hours at 2-8°C, Provided that Reconstitution/Dilution was Carried out Under Controlled and Validated Aseptic Conditions.
Body Weight (kg) | Volume of Voriconazole hameln Concentrate 10 mg/mL Required for: | ||||
Dose of 3 mg/kg Body Weight (Number of Vials) | Dose of 4 mg/kg Body Weight (Number of Vials) | Dose of 6 mg/kg Body Weight (Number of Vials) | Dose of 8 mg/kg Body Weight (Number of Vials) | Dose of 9 mg/kg Body Weight (Number of Vials) | |
10 | 4.0 mL (1) | 8.0 mL (1) | 9.0 mL (1) | ||
15 | 6.0 mL (1) | 12.0 mL (1) | 13.5 mL (1) | ||
20 | 8.0 mL (1) | 16.0 mL (1) | 18.0 mL (1) | ||
25 | 10.0 mL (1) | 20.0 mL (1) | 22.5 mL (2) | ||
30 | 9.0 mL (1) | 12.0 mL (1) | 18.0 mL (1) | 24.0 mL (2) | 27.0 mL (2) |
35 | 10.5 mL (1) | 14.0 mL (1) | 21.0 mL (2) | 28.0 mL (2) | 31.5 mL (2) |
40 | 12.0 mL (1) | 16.0 mL (1) | 24.0 mL (2) | 32.0 mL (2) | 36.0 mL (2) |
45 | 13.5 mL (1) | 18.0 mL (1) | 27.0 mL (2) | 36.0 mL (2) | 40.5 mL (3) |
50 | 15.0 mL (1) | 20.0 mL (1) | 30.0 mL (2) | 40.0 mL (2) | 45.0 mL (3) |
55 | 16.5 mL (1) | 22.0 mL (2) | 33.0 mL (2) | 44.0 mL (3) | 49.5 mL (3) |
60 | 18.0 mL (1) | 24.0 mL (2) | 36.0 mL (2) | 48.0 mL (3) | 54.0 mL (3) |
65 | 19.5 mL (1) | 26.0 mL (2) | 39.0 mL (2) | 52.0 mL (3) | 58.5 mL (3) |
70 | 21.0 mL (2) | 28.0 mL (2) | 42.0 mL (3) | ||
75 | 22.5 mL (2) | 30.0 mL (2) | 45.0 mL (3) | ||
80 | 24.0 mL (2) | 32.0 mL (2) | 48.0 mL (3) | ||
85 | 25.5 mL (2) | 34.0 mL (2) | 51.0 mL (3) | ||
90 | 27.0 mL (2) | 36.0 mL (2) | 54.0 mL (3) | ||
95 | 28.5 mL (2) | 38.0 mL (2) | 57.0 mL (3) | ||
100 | 30.0 mL (2) | 40.0 mL (2) | 60.0 mL (3) |
Reconstituted Voriconazole hameln Should be Diluted in a Compatible Infusion Solution Immediately Before Infusion.
The Concentrate can be Diluted in:
9 mg/mL (0.9%) Sodium Chloride Injection
Sodium Lactate Injection
5% Glucose and Lactated Ringer's Solution for Infusion
5% Glucose and 0.45% Sodium Chloride Solution for Infusion
5% Glucose Solution for Infusion
5% Glucose Solution with 20 mEq Potassium Chloride for Infusion
0.45% Sodium Chloride Solution for Infusion
5% Glucose and 0.9% Sodium Chloride Solution for Infusion
Compatibility of Voriconazole hameln with Other Solutions, other than those Listed Above (or in the "Incompatibilities" Section Below), has not been Established.
Voriconazole hameln Should not be Administered Concurrently with Other Medications in the Same Intravenous Line or Catheter, Including Parenteral Nutrition (e.g., Aminofusin 10% Plus).
Voriconazole hameln Should not be Used Concurrently with Blood Products.
Administration of Intravenous Infusions for Parenteral Nutrition may be Carried out Concurrently with Voriconazole, but not Through the Same Intravenous Access or Catheter.
4.2% Sodium Bicarbonate Solution for Infusion Should not be Used to Dilute Voriconazole hameln.
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.